secwatch.observer — SEC 8-K summary
======================================

Issuer:     FENNEC PHARMACEUTICALS INC. (FENC)
CIK:        0001211583
Form:       8-K
Filed at:   2022-03-24T23:59:59+00:00
Accession:  0001104659-22-037426
Event type: regulatory
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fennec resubmits NDA to FDA for PEDMARK to prevent pediatric ototoxicity
------------------------------------------------------------------------

- Resubmitted New Drug Application (NDA) for PEDMARK (sodium thiosulfate anhydrous injection).
- Indication: prevent platinum-induced ototoxicity in pediatric patients (1 month to <18 years) with localized solid tumors.
- CEO Rosty Raykov cited close work with FDA during the review process.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1211583/000110465922037426/0001104659-22-037426-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1211583/000110465922037426/tm2210369_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-037426

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer